Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Patout, C. Fercocq, A. Alanio, S. Touratier, E. Raffoux, F. Derouin, J.M. Molina, S. Bretagne, P. Ribaud, A. Bergeron (Paris, France). Breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving posaconazole prophylaxis (PPxis). Eur Respir J 2014; 44: Suppl. 58, 4685

Member's Comments

No comment yet.

Related content which might interest you: Serological-diagnosis of chronic pulmonary aspergillosis (CPA) and aspergillus lateral-flow device (LFD) Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections Year: 2014 Clinical characteristics of chronic pulmonary aspergillosis and colonization; retrospective analysis of patients with isolation of asperguillus species from respiratory samples Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Pulmonary nocardiosis (PN) complicating chronic pulmonary diseases Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Clinical characteristics and prognosis of chronic pulmonary aspergillosis Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Pulmonary fungal infection in immunocompetent vs immunocompromised patients - a retrospective study Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections Year: 2014 Pulmonary infections in neutropenic patients Source: Eur Respir J 2003; 22: Suppl. 45, 334s Year: 2003 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 The impact of mixed etiology in community acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Development of an antibody therapy for the treatment of pneumonia Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Opportunistic infections in patients with lung tuberculosis Source: International Congress 2015 – Case series and clinical conundrums in TB Year: 2015 Immunoglobulin levels and severity of community-acquired pneumonia (CAP) Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections Year: 2014 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Pulmonary aspergilloma (about 76 cases) Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Effectiveness of immune stimulatory therapy in patient with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Plaque-related vs. plaque-unrelated cardio and cerebrovascular events (CCVE) in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (ClinicalTrials: NCT01143155) Source: International Congress 2014 – Immunology of respiratory infections Year: 2014 Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014